Qian Qiao1, Weiguo Hu. 1. Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Abstract
BACKGROUND: The TP53 codon 72 polymorphism has been associated with the individual susceptibility to lung cancer. However, the association remains uncertain and varies with ethnicity, smoking status, cancer histology, and stage. METHODS: We performed a meta-analysis to evaluate the relationship between TP53 Arg72Pro polymorphism and lung cancer susceptibility basing on 15,647 lung cancer patients and 14,391 controls from 36 published literatures. We also performed stratified analysis in populations of different ethnicities, smoking statuses, lung cancer stages, and histological types. RESULTS: The analysis showed a significantly increased lung cancer susceptibility among Pro allele carriers (P < 0.001, odds ratio (OR) = 1.14, 95% confidence interval (CI) = 1.1-1.19), especially for smokers (P < 0.001, OR = 1.29, 95% CI = 1.12-1.47). Stratified analysis indicated that Pro72 elevates lung cancer susceptibility in Asians, while it has no effect on lung cancer risk of Caucasians. Moreover, Pro carriers present an increased risk of developing squamous cell carcinoma and adenocarcinoma, instead of large cell carcinoma and small cell carcinoma. Interestingly, patients with the Pro allele seemed to be diagnosed with lung cancer at the early stages (stage I-II, P = 0.008, OR = 1.2, 95% CI = 1.05-1.37). CONCLUSIONS: Our results suggest that the Pro allele acts as a risk factor for development of lung cancer, especially for smokers and Asians.
BACKGROUND: The TP53 codon 72 polymorphism has been associated with the individual susceptibility to lung cancer. However, the association remains uncertain and varies with ethnicity, smoking status, cancer histology, and stage. METHODS: We performed a meta-analysis to evaluate the relationship between TP53 Arg72Pro polymorphism and lung cancer susceptibility basing on 15,647 lung cancerpatients and 14,391 controls from 36 published literatures. We also performed stratified analysis in populations of different ethnicities, smoking statuses, lung cancer stages, and histological types. RESULTS: The analysis showed a significantly increased lung cancer susceptibility among Pro allele carriers (P < 0.001, odds ratio (OR) = 1.14, 95% confidence interval (CI) = 1.1-1.19), especially for smokers (P < 0.001, OR = 1.29, 95% CI = 1.12-1.47). Stratified analysis indicated that Pro72 elevates lung cancer susceptibility in Asians, while it has no effect on lung cancer risk of Caucasians. Moreover, Pro carriers present an increased risk of developing squamous cell carcinoma and adenocarcinoma, instead of large cell carcinoma and small cell carcinoma. Interestingly, patients with the Pro allele seemed to be diagnosed with lung cancer at the early stages (stage I-II, P = 0.008, OR = 1.2, 95% CI = 1.05-1.37). CONCLUSIONS: Our results suggest that the Pro allele acts as a risk factor for development of lung cancer, especially for smokers and Asians.
Authors: Hae-Yun Jung; Young Mi Whang; Jae Sook Sung; Hyoung Doo Shin; Byung Lae Park; Jun Suk Kim; Sang Won Shin; Hee Yun Seo; Jae Hong Seo; Yeul Hong Kim Journal: J Hum Genet Date: 2008-03-25 Impact factor: 3.172
Authors: N V Cherdyntseva; P A Gervas; N V Litvyakov; M N Stakcheeva; A A Ponomaryeva; A Yu Dobrodeev; E V Denisov; V A Belyavskaya; E L Choinzonov Journal: Exp Oncol Date: 2010-09
Authors: R Birgander; A Själander; A Rannug; A K Alexandrie; M I Sundberg; J Seidegård; G Tornling; G Beckman; L Beckman Journal: Carcinogenesis Date: 1995-09 Impact factor: 4.944
Authors: Lili Yan; Deqiang Zhang; Chengwen Chen; Yumin Mao; Yi Xie; Yao Li; Yan Huang; Baohui Han Journal: Int J Cancer Date: 2009-12-15 Impact factor: 7.396
Authors: A Weston; L S Perrin; K Forrester; R N Hoover; B F Trump; C C Harris; N E Caporaso Journal: Cancer Epidemiol Biomarkers Prev Date: 1992 Sep-Oct Impact factor: 4.254
Authors: Khadijah A Mitchell; Adriana Zingone; Leila Toulabi; Jacob Boeckelman; Bríd M Ryan Journal: Clin Cancer Res Date: 2017-12-01 Impact factor: 12.531
Authors: Lei Zhang; Yi Wang; Zhiqiang Qin; Ran Li; Rong Cong; Chengjian Ji; Xianghu Meng; Yamin Wang; Jiadong Xia; Ninghong Song Journal: J Cancer Date: 2018-09-08 Impact factor: 4.207
Authors: Robert Stoehr; Rebecca Weisser; Olaf Wendler; Johannes Giedl; Khalid Daifalla; Nadine T Gaisa; Georg Richter; Valentina Campean; Maximilian Burger; Bernd Wullich; Arndt Hartmann Journal: J Cancer Date: 2018-10-20 Impact factor: 4.207
Authors: Silvia Pineda; Roger L Milne; M Luz Calle; Nathaniel Rothman; Evangelina López de Maturana; Jesús Herranz; Manolis Kogevinas; Stephen J Chanock; Adonina Tardón; Mirari Márquez; Lin T Guey; Montserrat García-Closas; Josep Lloreta; Erin Baum; Anna González-Neira; Alfredo Carrato; Arcadi Navarro; Debra T Silverman; Francisco X Real; Núria Malats Journal: PLoS One Date: 2014-05-12 Impact factor: 3.240